Selective CB2 agonists with anti-pruritic activity: Discovery of potent and orally available bicyclic 2-pyridones
摘要:
The CB2 receptor has emerged as a potential target for the treatment of pruritus as well as pain without CB1-mediated side effects. We previously identified 2-pyridone derivatives 1 and 2 as potent CB2 agonists; however, this series of compounds was found to have unacceptable pharmacokinetic profiles with no significant effect in vivo. To improve these profiles, we performed further structural optimization of 1 and 2, which led to the discovery of bicyclic 2-pyridone 18e with improved CB2 affinity and selectivity over CB1. In a mouse pruritus model, 18e inhibited compound 48/80 induced scratching behavior at a dose of 100 mg/kg. In addition, the docking model of 18e with an active-state CB2 homology model indicated the structural basis of its high affinity and selectivity over CB1. (C) 2013 Published by Elsevier Ltd.
据报道,通过调节1-,5-和6-位侧链的大小,发现了基于3-氨基甲酰基-2-吡啶酮衍生物的新型CB2配体。该模板周围的结构-活性关系导致鉴定出S-777469为选择性CB2受体激动剂,该化合物在1.0 mg / kg po和10 mg / kg po下表现出对化合物48/80诱导的刮擦的显着抑制作用(55 %和61%)。
The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivatives by adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure–activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compound 48/80 at 1.0 mg/kg po and 10 mg/kg
据报道,通过调节1-,5-和6-位侧链的大小,发现了基于3-氨基甲酰基-2-吡啶酮衍生物的新型CB2配体。该模板周围的结构-活性关系导致鉴定出S-777469为选择性CB2受体激动剂,该化合物在1.0 mg / kg po和10 mg / kg po下表现出对化合物48/80诱导的刮擦的显着抑制作用(55 %和61%)。
Selective CB2 agonists with anti-pruritic activity: Discovery of potent and orally available bicyclic 2-pyridones
The CB2 receptor has emerged as a potential target for the treatment of pruritus as well as pain without CB1-mediated side effects. We previously identified 2-pyridone derivatives 1 and 2 as potent CB2 agonists; however, this series of compounds was found to have unacceptable pharmacokinetic profiles with no significant effect in vivo. To improve these profiles, we performed further structural optimization of 1 and 2, which led to the discovery of bicyclic 2-pyridone 18e with improved CB2 affinity and selectivity over CB1. In a mouse pruritus model, 18e inhibited compound 48/80 induced scratching behavior at a dose of 100 mg/kg. In addition, the docking model of 18e with an active-state CB2 homology model indicated the structural basis of its high affinity and selectivity over CB1. (C) 2013 Published by Elsevier Ltd.